[
  {
    "ts": "2025-12-02T09:00:00+00:00",
    "headline": "Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy",
    "summary": "Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (",
    "url": "https://finance.yahoo.com/news/antengene-announces-ind-approval-china-090000940.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "1fd5079a-afb0-304a-be8d-b909c9e87124",
      "content": {
        "id": "1fd5079a-afb0-304a-be8d-b909c9e87124",
        "contentType": "STORY",
        "title": "Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy",
        "description": "",
        "summary": "Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (",
        "pubDate": "2025-12-02T09:00:00Z",
        "displayTime": "2025-12-02T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583",
          "originalWidth": 400,
          "originalHeight": 170,
          "caption": "Logo (PRNewsfoto/Antengene Corporation Limited)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iX4d3zH6.489mYmi5zPGYg--~B/aD0xNzA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583.cf.webp",
              "width": 400,
              "height": 170,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p3TrWaua._04_VbJue7uzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/antengene-announces-ind-approval-china-090000940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/antengene-announces-ind-approval-china-090000940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "6996.HK"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]